WuXi, I-Mab col­lab­o­rate to de­velop 3 bis­pe­cific an­ti­bod­ies

BioSpectrum (Asia) - - Company -

WuXi Bi­o­log­ics, a lead­ing global open-ac­cess bi­o­log­ics tech­nol­ogy plat­form com­pany of­fer­ing endto-end so­lu­tions for bi­o­log­ics dis­cov­ery, de­vel­op­ment and man­u­fac­tur­ing and I-Mab Bio­pharma, a biotech com­pany fo­cus­ing ex­clu­sively on in­no­va­tive bi­o­log­ics in im­muno-on­col­ogy and auto-im­mune dis­eases, have jointly an­nounced that I-Mab has ex­panded strate­gic col­lab­o­ra­tion with WuXi Bi­o­log­ics and li­censed pro­pri­etary WuXiBody Plat­form to de­velop three bis­pe­cific an­ti­bod­ies. WuXi Bi­o­log­ics will also be the ex­clu­sive part­ner to de­velop and man­u­fac­ture th­ese bis­pecifics.

Un­der the terms of the agree­ment, I-Mab has rights to use the pro­pri­etary WuXiBody Plat­form to re­search, de­velop and com­mer­cial­ize three bis­pe­cific an­ti­bod­ies gen­er­ated from I-MAB’s pro­pri­etary pipe­line. WuXi Bi­o­log­ics will re­ceive an up­front pay­ment as well as de­vel­op­ment, reg­u­la­tory and com­mer­cial mile­stone pay­ments, and will be en­ti­tled to roy­al­ties based on global sales of th­ese bis­pe­cific an­ti­bod­ies.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.